Angel investors are the first stop in a new era of drug development image

Newsworks, May 11, 2017
Elana Gordon, quoting Rachel Sachs


Read the full article

From the article:

So is this really the best way to develop new healthcare technologies and therapies?

"So there are pros and there are cons," said Rachel Sachs, a law professor at Washington University in St. Louis who studies policy in the innovation and biotech area.

On the plus side, "a number of small companies exploring a number of new, innovative ideas, might mean that we get breakthroughs more quickly than if you have a few old pharmaceutical companies who are stuck in their ways," she said. "If we have a bunch of small, innovative companies, which are maybe able to take on different kinds of risks than older established companies ... We may be able to learn unexpected things more quickly than we otherwise would."

Read more here!

biotechnology fda health care finance health law policy pharmaceuticals public health rachel sachs